JP2009533476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533476A5 JP2009533476A5 JP2009505655A JP2009505655A JP2009533476A5 JP 2009533476 A5 JP2009533476 A5 JP 2009533476A5 JP 2009505655 A JP2009505655 A JP 2009505655A JP 2009505655 A JP2009505655 A JP 2009505655A JP 2009533476 A5 JP2009533476 A5 JP 2009533476A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- molecule
- diketopiperazine
- solution
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 59
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 51
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 51
- 238000000034 method Methods 0.000 claims 30
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 24
- 239000002245 particle Substances 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000000843 powder Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 230000000065 osmolyte Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000001925 catabolic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims 1
- -1 glutaryl Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74488206P | 2006-04-14 | 2006-04-14 | |
| US60/744,882 | 2006-04-14 | ||
| PCT/US2007/066728 WO2007121411A2 (en) | 2006-04-14 | 2007-04-16 | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191549A Division JP5898156B2 (ja) | 2006-04-14 | 2013-09-17 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533476A JP2009533476A (ja) | 2009-09-17 |
| JP2009533476A5 true JP2009533476A5 (cg-RX-API-DMAC7.html) | 2010-05-27 |
| JP5415938B2 JP5415938B2 (ja) | 2014-02-12 |
Family
ID=38567214
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505655A Expired - Fee Related JP5415938B2 (ja) | 2006-04-14 | 2007-04-16 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
| JP2013191549A Active JP5898156B2 (ja) | 2006-04-14 | 2013-09-17 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
| JP2015233125A Pending JP2016104736A (ja) | 2006-04-14 | 2015-11-30 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191549A Active JP5898156B2 (ja) | 2006-04-14 | 2013-09-17 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
| JP2015233125A Pending JP2016104736A (ja) | 2006-04-14 | 2015-11-30 | グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2010155A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5415938B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20150042304A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104288756A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007238000B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0709964A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2646400A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1206241A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008013216A (cg-RX-API-DMAC7.html) |
| RU (3) | RU2542500C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007121411A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2377204C (en) | 1999-06-29 | 2015-01-20 | Pharmaceutical Discovery Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| IN2014DN09128A (cg-RX-API-DMAC7.html) | 2005-09-14 | 2015-07-10 | Mannkind Corp | |
| CN101389348A (zh) | 2006-02-22 | 2009-03-18 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| KR20150042304A (ko) * | 2006-04-14 | 2015-04-20 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| AU2008316636B2 (en) | 2007-10-24 | 2014-02-06 | Mannkind Corporation | Delivery of active agents |
| HUE025485T2 (en) | 2007-10-24 | 2016-02-29 | Mannkind Corp | Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration |
| US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
| JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
| CN109568740B (zh) | 2008-06-13 | 2022-05-27 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| BR122020002400B1 (pt) | 2008-06-20 | 2021-12-07 | Mannkind Corporation | Sistema de detecção de inalação de pó seco e sistema de monitoramento acoplável para um inalador de pó seco |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| JP5918539B2 (ja) | 2009-01-08 | 2016-05-18 | マンカインド コーポレイション | Ｇｌｐ−１を用いる高血糖症の治療方法 |
| KR101733816B1 (ko) * | 2009-03-04 | 2017-05-08 | 맨카인드 코포레이션 | 개선된 건조 분말 약물 전달 시스템 |
| PL2405963T3 (pl) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Urządzenie, układ i sposób pomiaru oporu inhalatora |
| CA2764505C (en) | 2009-06-12 | 2018-09-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| ES2880102T3 (es) | 2009-06-12 | 2021-11-23 | Mannkind Corp | Micropartículas de dicetopiperazina con contenido de isómeros definido |
| WO2011017554A2 (en) * | 2009-08-07 | 2011-02-10 | Mannkind Corporation | Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
| WO2012033792A2 (en) | 2010-09-07 | 2012-03-15 | Dmi Acquisition Corp. | Treatment of diseases |
| JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| EA028343B1 (ru) | 2011-10-10 | 2017-11-30 | Ампио Фармасьютикалз, Инк. | Лечение дегенеративного заболевания сустава |
| PH12014500686A1 (en) | 2011-10-10 | 2020-12-18 | Ampio Pharmaceuticals Inc | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| MX355446B (es) | 2011-10-28 | 2018-04-18 | Ampio Pharmaceuticals Inc | Tratamiento de rinitis. |
| JP6059802B2 (ja) | 2012-07-01 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 長時間作用型ｇｌｐ−１ペプチドの使用 |
| CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| JP2015526523A (ja) * | 2012-08-29 | 2015-09-10 | マンカインド コーポレイション | 高血糖症の治療のための方法および組成物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| RS57531B1 (sr) | 2012-12-21 | 2018-10-31 | Sanofi Sa | Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti |
| MX392016B (es) * | 2013-03-15 | 2025-03-21 | Mannkind Corp | Composiciones de dicetopiperazina microcristalina y métodos. |
| US9808454B2 (en) | 2013-03-15 | 2017-11-07 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
| EP3035952B1 (en) | 2013-08-22 | 2018-12-26 | ZP Opco, Inc. | Stable glucagon peptide formulations |
| US9782344B2 (en) | 2013-08-22 | 2017-10-10 | Zp Opco, Inc. | Stable glucagon peptide formulations |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EA034620B1 (ru) | 2014-03-18 | 2020-02-27 | Апептико Форшунг Унд Энтвиклунг Гмбх | Пептидный медикамент в виде сухого порошка |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN108066762B (zh) * | 2016-11-07 | 2022-04-01 | 赫兰 | Glp-1受体激动剂类药物的用途 |
| BR112020006246A2 (pt) | 2017-10-12 | 2021-03-30 | Novo Nordisk A/S | Método para controle do peso de um sujeito em necessidade |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN109827875A (zh) * | 2019-04-10 | 2019-05-31 | 上海市食品药品检验所 | 一种用于测定吸入制剂溶出度的装置和方法 |
| KR20210062509A (ko) | 2019-11-21 | 2021-05-31 | 대한민국(전북기계공업고등학교장) | 필터리스 다이나믹 미세먼지 공기 청정기 |
| CN115192554A (zh) * | 2022-08-08 | 2022-10-18 | 浙江仙琚萃泽医药科技有限公司 | 无抛射剂的含肽吸入溶液剂及其制备方法 |
| WO2025159538A1 (ko) * | 2024-01-26 | 2025-07-31 | 주식회사 아울바이오 | Glp-1 ra 기반 계열 펩타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물 |
| WO2025220834A1 (ko) | 2024-04-16 | 2025-10-23 | 한미약품 주식회사 | 흡입제 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352461A (en) * | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| EP1012188B1 (de) * | 1997-09-12 | 2004-08-18 | Pharis Biotec GmbH | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
| CA2377204C (en) * | 1999-06-29 | 2015-01-20 | Pharmaceutical Discovery Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| AU2002308706A1 (en) * | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| JP4417113B2 (ja) * | 2002-02-20 | 2010-02-17 | エミスフェアー・テクノロジーズ・インク | Ｇｌｐ−１分子の投与方法 |
| WO2003075834A2 (en) * | 2002-03-08 | 2003-09-18 | Eli Lilly And Company | Activated protein c formulations |
| WO2004012672A2 (en) * | 2002-08-01 | 2004-02-12 | Mannkind Corporation | Cell transport compositions and uses thereof |
| US20040038865A1 (en) * | 2002-08-01 | 2004-02-26 | Mannkind Corporation | Cell transport compositions and uses thereof |
| PL1631264T5 (pl) * | 2003-06-02 | 2018-09-28 | Glaxosmithkline Biologicals Sa | Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca |
| CN104436170B (zh) * | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| IN2014DN09128A (cg-RX-API-DMAC7.html) * | 2005-09-14 | 2015-07-10 | Mannkind Corp | |
| CN101389348A (zh) * | 2006-02-22 | 2009-03-18 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| KR20150042304A (ko) * | 2006-04-14 | 2015-04-20 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
-
2007
- 2007-04-16 KR KR1020157008571A patent/KR20150042304A/ko not_active Ceased
- 2007-04-16 JP JP2009505655A patent/JP5415938B2/ja not_active Expired - Fee Related
- 2007-04-16 BR BRPI0709964-9A patent/BRPI0709964A2/pt not_active IP Right Cessation
- 2007-04-16 MX MX2008013216A patent/MX2008013216A/es active IP Right Grant
- 2007-04-16 EP EP20070760728 patent/EP2010155A2/en not_active Withdrawn
- 2007-04-16 AU AU2007238000A patent/AU2007238000B2/en not_active Ceased
- 2007-04-16 CN CN201410514033.8A patent/CN104288756A/zh active Pending
- 2007-04-16 RU RU2010137392/15A patent/RU2542500C2/ru not_active IP Right Cessation
- 2007-04-16 RU RU2008144965/15A patent/RU2409349C2/ru not_active IP Right Cessation
- 2007-04-16 KR KR1020147011316A patent/KR101558829B1/ko active Active
- 2007-04-16 KR KR1020087027774A patent/KR101438839B1/ko active Active
- 2007-04-16 CN CNA200780013424XA patent/CN101453988A/zh active Pending
- 2007-04-16 WO PCT/US2007/066728 patent/WO2007121411A2/en not_active Ceased
- 2007-04-16 CA CA002646400A patent/CA2646400A1/en active Pending
-
2013
- 2013-09-17 JP JP2013191549A patent/JP5898156B2/ja active Active
-
2014
- 2014-12-23 RU RU2014152320A patent/RU2014152320A/ru not_active Application Discontinuation
-
2015
- 2015-07-16 HK HK15106772.4A patent/HK1206241A1/xx unknown
- 2015-11-30 JP JP2015233125A patent/JP2016104736A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533476A5 (cg-RX-API-DMAC7.html) | ||
| WO2011017554A4 (en) | Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome | |
| RU2008144965A (ru) | Фармацевтические композиции, содержащие глюкагон-подобный пептид (glp-1) | |
| US20230390206A1 (en) | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces | |
| CN101663282B (zh) | 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 | |
| US20100168011A1 (en) | Pharmaceutical Formulations and Methods for Making the Same | |
| CN110022902A (zh) | 包含glp-1/胰高血糖素双重激动剂、接头和透明质酸的缀合物 | |
| NZ534125A (en) | A formulation comprising a GLP-1 compound and a delivery agent | |
| IL181516A (en) | Use of Dictopyprazine, Dictomorphine and Dictodeoxane salts for the preparation of medicinal preparations | |
| JP2008504249A (ja) | 糖尿病を治療するための方法 | |
| US20110046052A1 (en) | Excipients for Protein Stabilization | |
| KR20200106892A (ko) | pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액 | |
| EP3720472A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| EP3373953B1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| EP4360645A1 (en) | Pharmaceutical composition containing glp-1 compound | |
| HK40025124A (en) | Composition for injection |